Skip to content
zameds

2009 v-l, 2010, 2011, 361, california, influenza virus a, influenza virus b, victoria, wisconsin

Sold as Influvac subunit

Combination product

This product contains more than one active ingredient, so it has no single molecular structure.

Background

Loading...
Loading Wikipedia summary

Registration

Applicants
1
Registrations
1

Applicants and registrations

ApplicantBrandsDosagesRegistrationsScheduleLeaflets
Abbott Laboratories S.A. (Pty) LtdCertificate held by Abbott Laboratories South Africa (Pty) LtdInfluvac subunit15 μgT0581Not determinedPIPIL

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Influvac subunit 2021

EACH 0,5 ml SYRINGE CONTAINS INFLUENZA VIRUS A/CALIFORNIA/7/2009(H1N1)V-L 15,0 ugINFLUENZA VIRUS A/VICTORIA/361/2011 (H3N2) 15,0 ugINFLUENZA VIRUS B/WISCONSIN/1/2010 15,0 ug

15 μgSuspension for injection in prefilled syringe.T0581T/30.1/581Approved 20 February 2024RegisteredNot determinedPIPIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Professional information (PI)For healthcare professionalsInfluvac subunit 2021, Abbott Laboratories S.A. (Pty) LtdPatient information leaflet (PIL)For patients and carersInfluvac subunit 2021, Abbott Laboratories S.A. (Pty) Ltd

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading...
Loading PubMed articles